Answers are grounded in this paper and cite their sources.
Randomized trial demonstrates that providing e-cigarettes reduces cigarette consumption and carbon monoxide in adults treated for opioid use disorder, indicating a viable harm reduction strategy.
Introduction Most adults with opioid use disorder (OUD) smoke cigarettes, and cessation rates with FDA-approved medications are low. Switching to e-cigarettes (EC) is an effective cigarette reduction method in adults without OUD but has not been rigorously evaluated in adults with OUD. Methods Adults (N=41) in OUD treatment who smoked >5 cigarettes/day (CPD), used EC <3 of prior 30days, and did not want to quit smoking, were randomized to receive an 8 week supply of NIDA’s standardized research EC immediately (SREC, n=22) or after an 8-week delay (waitlist control; WLC, n=19). Participants reported past 24-hr CPD and EC use in daily texts for 8 weeks and research assessments and biochemical monitoring (e.g., carbon monoxide [CO]) every 2 weeks for 8 weeks. Results Participants had a mean age of 50, were 76% male, 88% white. From Baseline (BL) to Week 8, the change in CPD differed significantly between groups (p=0.001) with a larger decrease in CPD in SREC vs. WLC (SREC 15.3 at BL to 7.2 CPD at W8, WLC 14.2 to 12.8). There was a significant reduction in breath CO levels within SREC across the 8-weeks (from 22.9 at BL to 12.5 at W8, p<0.001), that was larger than WLC (23.7 vs. 20.3, p=0.042) (group x time p=0.071). No group differences were observed on nicotine dependence, withdrawal, or OUD stability (p’s>0.05). Conclusions Provision of ECs to people with OUD who smoke, not planning to quit, resulted in reduced combusted tobacco use, exposure and no worsening withdrawal, dependence, or OUD stability.
No takes yet. Share an insight, caveat, or question.
Streck et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: